mTOR Inhibitors for Treatment of Low-Risk Prostate Cancer

Prostate cancer incidence increases with age; along with many other cancers, it could be considered a disease of aging. Prostate cancer screening has led to a significant proportion of men diagnosed with low-grade, low-stage prostate cancer who are now more likely to choose an active surveillance strategy rather than definitive treatments. Definitive treatment, such as surgery and radiation therapy, is useful for high-grade disease; however, because of the low long-term risk of progression of a low-grade disease and side effects of surgery and radiation, these treatments are less commonly used for low-grade disease.

Source: Medical Hypotheses - June 5, 2018 Category: Biomedical Science Authors: Michael A. Liss, Lanette Rickborn, John DiGiovanni, Dean Bacich, Linda A. DeGraffenried, Manish Parihar, Ian M. Thompson, Zelton Dave Sharp Source Type: research